Original ContributionSchedule-Dependent Apoptosis in K-ras Mutant Non–Small-Cell Lung Cancer Cell Lines Treated with Docetaxel and Erlotinib: Rationale for Pharmacodynamic Separation
References (17)
- et al.
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-smallcell lung cancer
Clin Lung Cancer
(2006) - et al.
Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies
Clin Lung Cancer
(2007) - et al.
Erlotinib in previously treated non-small-cell lung cancer
N Engl J Med
(2005) - et al.
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
J Clin Oncol
(2005) - et al.
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial
J Clin Oncol
(2007) - et al.
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2
J Clin Oncol
(2004) - et al.
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 1
J Clin Oncol
(2004) - et al.
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255
Cancer Res
(2004)
There are more references available in the full text version of this article.
Cited by (0)
Electronic forwarding or copying is a violation of US and International Copyright Laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1525-7304, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.
Copyright © 2007 Elsevier Inc. All rights reserved.